Empiric Therapy with Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Results from the INCREMENT Cohort

Clinical Infectious Diseases

Volumn 65, Issue 10, 2017, Pages 1615-1623

  Palacios Baena, Zaira Raquel ^a   Gutiérrez Gutiérrez, Belén ^a   Calbo, Esther ^b   Almirante, Benito ^c   Viale, Pierluigi ^d   Oliver, Antonio ^e   Pintado, Vicente ^f   Gasch, Oriol ^g   Martínez Martínez, Luis ^h   Pitout, Johann ⁱ   Akova, Murat ^j   Peña, Carmen ^k   Molina Gil Bermejo, José ^a   Hernández, Alicia ^l   Venditti, Mario ^m   Prim, Nuria ⁿ   Bou, German ^o   Tacconelli, Evelina ^p   Tumbarello, Mario ^q   Hamprecht, Axel ^r   Giamarellou, Helen ^s   Almela, Manel ^t   Pérez, Federico ^u   Schwaber, Mitchell J ^v   Bermejo, Joaquín ^w   Lowman, Warren ^x   Hsueh, Po Ren ^y   Paño Pardo, José Ramón ^z   Torre Cisneros, Julián ^aa   Souli, Maria ^ab   Bonomo, Robert A ^ac   Carmeli, Yehuda ^v   Paterson, David L ^ad   Pascual, Álvaro ^a   Rodríguez Baño, Jesús ^a   Galvez J ^a   Falcone, M ^m   Russo, A ^m   Daikos, G ^ae   Trecarichi, E M ^q   Losito, A R ^q   Gomez J ^l   Iosifidis, E ^af   Roilides, E ^af   Karaiskos, I ^s   Doi, Y ^ag   Tuon, F F ^ah   Navarro, F ⁿ   Mirelis, B ⁿ   Martinez J A ^t   De La Calle, C ^t   Morata, L ^ai   San Juan, R ^ai   Fernandez Ruiz M ^c   Larrosa, N ^c   Puig, M ^c   Molina, J ^a   Gonzalez V ^a   Rucci, V ^w   Ruiz De Gopegui, E ^e   Marinescu, C I ^e   Farinas M C ^h   Cano, M E ^h   Gozalo, M ^h   Mora Rillo, M ^aj   Gomez Zorrilla S ^k   Tubau, F ^k   Pournaras, S ^ak   Tsakris, A ^ak   Zarkotou, O ^ak   Azap, O K ^al   Antoniadou, A ^ak   Poulakou, G ^ak   Virmani, D ⁱ   Cano, A ^aa   Machuca, I ^aa   Helvaci, O ^j   Sahin, A O ^j   Ruiz Garbajosa, P ^f   Bartoletti, M ^d   Giannella, M ^d   Peter, S ^p   Badia, C ^b   Xercavins, M ^b   Fontanals, D ^am   Jove E ^am   more..

^a HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^b HOSPITAL MÚTUA DE TERRASSA   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^f HOSPITAL RAMÓN Y CAJAL   (Spain)

^g Parc Tauli Health Corporation   (Spain)

^h HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

ⁱ UNIVERSITY OF CALGARY   (Canada)

^j HACETTEPE UNIVERSITY   (Turkey)

^k HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^l HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^m POLICLINICO UMBERTO I   (Italy)

ⁿ HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^o HOSPITAL JUAN CANALEJO   (Spain)

^p UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^q CATHOLIC UNIVERSITY   (Italy)

^r UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^s IASO GENERAL HOSPITAL   (Greece)

^t HOSPITAL CLÍNIC   (Spain)

^u CASE WESTERN RESERVE UNIVERSITY   (United States)

^v TEL AVIV UNIVERSITY   (Israel)

^w HOSPITAL ESPAÑOL   (Argentina)

^x University of the Witwatersrand   (South Africa)

^y NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^z HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^aa HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^ab NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^ac CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^ad UNIVERSITY OF QUEENSLAND   (Australia)

^ae LAIKO GENERAL HOSPITAL   (Greece)

^af Aristotle University and Hippokration General Hospital   (Greece)

^ag UNIVERSITY OF PITTSBURGH   (United States)

^ah FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^ai HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^aj HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

^ak UNIVERSITY OF ATHENS   (Greece)

^al BASKENT UNIVERSITY   (Turkey)

^am HOSPITAL DE SABADELL   (Spain)

more..

Author keywords

aminoglycosides; antimicrobial resistance; bloodstream infections; extended spectrum ? lactamase producing Enterobacteriaceae; therapy

Indexed keywords

AMINOGLYCOSIDE; AZTREONAM; CARBAPENEM; CEPHALOSPORIN DERIVATIVE; COLISTIN; COTRIMOXAZOLE; DORIPENEM; ERTAPENEM; FOSFOMYCIN; IMIPENEM; MEROPENEM; QUINOLONE DERIVATIVE; TIGECYCLINE; ANTIINFECTIVE AGENT; BETA LACTAMASE; CARBAPENEM DERIVATIVE;

ADULT; ALL CAUSE MORTALITY; ANTIBIOTIC THERAPY; ARTICLE; BLOODSTREAM INFECTION; CLINICAL OUTCOME; COHORT ANALYSIS; ENTEROBACTERIACEAE INFECTION; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; FEMALE; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; MULTICENTER STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; BACTEREMIA; BETA-LACTAM RESISTANCE; DRUG EFFECT; ENTEROBACTERIACEAE; ENZYMOLOGY; KAPLAN MEIER METHOD; MICROBIOLOGY; MIDDLE AGED;

ANTI-BACTERIAL AGENTS; BACTEREMIA; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CARBAPENEMS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 85032746020     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cix606     Document Type: Article

References (27)

1. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 2005; 18:657-86.
2. Rodriguez-Bano J, Pascual A. Clinical significance of extended-spectrum beta-lactamases. Expert Rev Anti Infect Ther 2008; 6:671-83.
3. Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008; 8:159-66.
4. Van Duin D, Doi Y. The global epidemiology of carbapenemase-producing Enterobacteriaceae. Virulence 2016; 11:1-10.
5. Rodriguez-Bano J, Navarro MD, Retamar P, Picon E, Pascual A; Extended-Spectrum Beta-Lactamases-Red Espanola de Investigacion en Patologia Infecciosa/Grupo de Estudio de Infeccion Hospitalaria Group. β-Lactam/-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis 2012; 54:167-74.
6. Harris PN, Yin M, Jureen R, et al. Comparable outcomes for β-lactam/-lactamase inhibitor combinations and carbapenems in definitive treatment of bloodstream infections caused by cefotaxime-resistant Escherichia coli or Klebsiella pneumoniae. Antimicrob Resist Infect Control 2015; 4:14.
7. Gutierrez-Gutierrez B, Perez-Galera S, Salamanca E, et al. A multinational, preregistered cohort study of β-lactam/-lactamase inhibitor combinations for treatment of bloodstream infections due to extended-spectrum-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2016; 60:4159-69.
8. Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum lactamases: a systematic review and meta-analysis. J Antimicrob Chemother 2012; 67:2793-803.
9. Gutierrez-Gutierrez B, Bonomo RA, Carmeli Y, et al; REIPI/ESGBIS/ INCREMENT Group. Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study. J Antimicrob Chemother 2016; 71:1672-80.
10. Palacios-Baena ZR, Gutierrez-Gutierrez B, De Cueto M, et al; REIPI/ESGBIS/ INCREMENT Group. Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother 2017; 72:906-13.
11. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 2008; 61:344-9.
12. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40:373-83.
13. Hilf M, Yu VL, Sharp J, Zuravleff JJ, Korvick JA, Muder RR. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med 1989; 87:540-6.
14. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008; 36:309-32.
15. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit CareMed 1992; 20: 864-74.
16. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 20th informational supplement, M100-S20. Wayne, PA: CLSI, 2010.
17. Kengkla K, Charoensuk N, Chaichana M, et al. Clinical risk scoring system for predicting extended-spectrum β-lactamase-producing Escherichia coli infection in hospitalized patients. J Hosp Infect 2016; 93:49-56.
18. MacGowan A. Breakpoints for extended-spectrum beta-lactamase-producing Enterobacteriacae: pharmacokinetic/pharmacodynamic considerations. Clin Microbiol Infect 2008; 14(suppl 1):166-8.
19. Wang R, Cosgrove SE, Tschudin-Sutter S, et al. Cefepime therapy for cefepime-susceptible extended-spectrum β-lactamase-producing Enterobacteriaceae bacteremia. Open Forum Infect Dis 2016; 3:ofw132.
20. Lee NY, Lee CC, Huang WH, Tsui KC, Hsueh PR, Ko WC. Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters. Clin Infect Dis 2013; 56:488-95.
21. Briales A, Rodriguez-Martinez JM, Velasco C, et al. Prevalence of plasmid-mediated quinolone resistance determinants qnr and aac(6')-Ib-cr in Escherichia coli and Klebsiella pneumoniae producing extended-spectrum β-lactamases in Spain. Int J Antimicrob Agents 2012; 39:431-4.
22. Hawser SP, Badal RE, Bouchillon SK, et al. Susceptibility of gram-negative aerobic bacilli from intra-abdominal pathogens to antimicrobial agents collected in the United States during 2011. J Infect 2014; 68:71-6.
23. Cha MK, Kang CI, Kim SH, et al; Korean Network for Study on Infectious Diseases (KONSID). In vitro activities of 21 antimicrobial agents alone and in combination with aminoglycosides or fluoroquinolones against extended-spectrum-lactamase-producing Escherichia coli isolates causing bacteremia. Antimicrob Agents Chemother 2015; 59:5834-7.
24. Ruiz de Alegria C, Rodriguez-Bano J, Cano ME, et al. Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases in Spain: microbiological and clinical features. J Clin Microbiol 2011; 49:1134-6.
25. Vidal L, Gafter-Gvili A, Borok S, Fraser A, Leibovici L, Paul M. Efficacy and safety of aminoglycoside monotherapy: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2007; 60:247-57.
26. Ipekci T, Seyman D, Berk H, Celik O. Clinical and bacteriological efficacy of amikacin in the treatment of lower urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella pneumoniae. J Infect Chemother 2014; 20:762-7.
27. Han SB, Lee SC, Lee SY, Jeong DC, Kang JH. Aminoglycoside therapy for childhood urinary tract infection due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae. BMC Infect Dis 2015; 15:414.